AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as in vivo models resistant to KRAS G12C inhibitors.



4984_Integrated platform enables KRAS-targeted drugs discovery_final - Copy

Download

← Return to Resources

Related Content

The Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...

VIEW RESOURCE

The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Previously viewed as undruggable,...

VIEW RESOURCE
← View all Biochemical Assays Resources
× peptide, amino acid

Contact An Expert Today!